CN101773478A - 一种兽用头孢噻呋盐酸盐的肺靶向微球及制备方法 - Google Patents
一种兽用头孢噻呋盐酸盐的肺靶向微球及制备方法 Download PDFInfo
- Publication number
- CN101773478A CN101773478A CN201010129187A CN201010129187A CN101773478A CN 101773478 A CN101773478 A CN 101773478A CN 201010129187 A CN201010129187 A CN 201010129187A CN 201010129187 A CN201010129187 A CN 201010129187A CN 101773478 A CN101773478 A CN 101773478A
- Authority
- CN
- China
- Prior art keywords
- ceftiofur hydrochloride
- glycolic acid
- preparation
- polylactic
- lung
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000004005 microsphere Substances 0.000 title claims abstract description 53
- KEQFDTJEEQKVLM-JUODUXDSSA-N (6r,7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-(furan-2-carbonylsulfanylmethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;hydron;chloride Chemical compound Cl.S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC(=O)C1=CC=CO1 KEQFDTJEEQKVLM-JUODUXDSSA-N 0.000 title claims abstract description 33
- 229960001356 ceftiofur hydrochloride Drugs 0.000 title claims abstract description 33
- 238000002360 preparation method Methods 0.000 title claims abstract description 23
- 230000008685 targeting Effects 0.000 title abstract description 9
- 230000002685 pulmonary effect Effects 0.000 title abstract description 8
- 238000001694 spray drying Methods 0.000 claims abstract description 15
- 239000002245 particle Substances 0.000 claims abstract description 13
- 239000012876 carrier material Substances 0.000 claims abstract description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 42
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 39
- 229960004275 glycolic acid Drugs 0.000 claims description 24
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 15
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 12
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 12
- 238000005303 weighing Methods 0.000 claims description 12
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 10
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 10
- 239000007921 spray Substances 0.000 claims description 10
- 239000000243 solution Substances 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 9
- 239000004310 lactic acid Substances 0.000 claims description 6
- 235000014655 lactic acid Nutrition 0.000 claims description 6
- 239000011259 mixed solution Substances 0.000 claims description 6
- 239000003814 drug Substances 0.000 abstract description 44
- 229940079593 drug Drugs 0.000 abstract description 16
- 238000000034 method Methods 0.000 abstract description 15
- 238000011068 loading method Methods 0.000 abstract description 7
- 210000004072 lung Anatomy 0.000 abstract description 7
- 230000001225 therapeutic effect Effects 0.000 abstract description 4
- 239000002699 waste material Substances 0.000 abstract description 3
- 206010059866 Drug resistance Diseases 0.000 abstract description 2
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 abstract 1
- 238000005538 encapsulation Methods 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 11
- ZBHXIWJRIFEVQY-IHMPYVIRSA-N ceftiofur Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC(=O)C1=CC=CO1 ZBHXIWJRIFEVQY-IHMPYVIRSA-N 0.000 description 8
- 229960005229 ceftiofur Drugs 0.000 description 7
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- 238000004090 dissolution Methods 0.000 description 5
- 238000007906 compression Methods 0.000 description 4
- 230000006835 compression Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical group O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000000843 anti-fungal effect Effects 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 230000007096 poisonous effect Effects 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 1
- RFLHUYUQCKHUKS-JUODUXDSSA-M Ceftiofur sodium Chemical compound [Na+].S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC(=O)C1=CC=CO1 RFLHUYUQCKHUKS-JUODUXDSSA-M 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000000680 avirulence Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 229960004467 ceftiofur sodium Drugs 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000000385 dialysis solution Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000002296 dynamic light scattering Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- VUZPPFZMUPKLLV-UHFFFAOYSA-N methane;hydrate Chemical compound C.O VUZPPFZMUPKLLV-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000002077 nanosphere Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 150000003952 β-lactams Chemical class 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010101291877A CN101773478B (zh) | 2010-03-22 | 2010-03-22 | 一种兽用头孢噻呋盐酸盐的肺靶向微球及制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010101291877A CN101773478B (zh) | 2010-03-22 | 2010-03-22 | 一种兽用头孢噻呋盐酸盐的肺靶向微球及制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101773478A true CN101773478A (zh) | 2010-07-14 |
CN101773478B CN101773478B (zh) | 2012-09-05 |
Family
ID=42510155
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2010101291877A Expired - Fee Related CN101773478B (zh) | 2010-03-22 | 2010-03-22 | 一种兽用头孢噻呋盐酸盐的肺靶向微球及制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101773478B (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013071456A3 (es) * | 2011-11-18 | 2013-08-01 | Universidad De Santiago De Chile | Microparticles comprising a polylactic- glycolic polymer and an antimicrobial agent selected from ceftiofur or florfenicol |
CN106474087A (zh) * | 2015-09-01 | 2017-03-08 | 瑞普(天津)生物药业有限公司 | 一种头孢喹肟微球凝胶复合制剂及其制备方法 |
CN107157940A (zh) * | 2017-07-07 | 2017-09-15 | 青岛农业大学 | 一种肺靶向硫酸头孢喹诺明胶微球及其制备方法 |
CN107308118A (zh) * | 2017-07-07 | 2017-11-03 | 青岛农业大学 | 一种肺靶向硫酸头孢喹诺plga微球及其制备方法 |
CN107320452A (zh) * | 2017-07-07 | 2017-11-07 | 青岛农业大学 | 一种肺靶向硫酸头孢喹诺ec微球及其制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1444946A (zh) * | 2002-03-20 | 2003-10-01 | 方淑昌 | 阿维菌素类药物纳米微球的制备方法及用途 |
CN1985832A (zh) * | 2005-12-21 | 2007-06-27 | 天津市润拓生物技术有限公司 | 一种畜禽使用的头孢哌酮肺靶向微球及其制备方法 |
-
2010
- 2010-03-22 CN CN2010101291877A patent/CN101773478B/zh not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1444946A (zh) * | 2002-03-20 | 2003-10-01 | 方淑昌 | 阿维菌素类药物纳米微球的制备方法及用途 |
CN1985832A (zh) * | 2005-12-21 | 2007-06-27 | 天津市润拓生物技术有限公司 | 一种畜禽使用的头孢哌酮肺靶向微球及其制备方法 |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013071456A3 (es) * | 2011-11-18 | 2013-08-01 | Universidad De Santiago De Chile | Microparticles comprising a polylactic- glycolic polymer and an antimicrobial agent selected from ceftiofur or florfenicol |
CN106474087A (zh) * | 2015-09-01 | 2017-03-08 | 瑞普(天津)生物药业有限公司 | 一种头孢喹肟微球凝胶复合制剂及其制备方法 |
CN107157940A (zh) * | 2017-07-07 | 2017-09-15 | 青岛农业大学 | 一种肺靶向硫酸头孢喹诺明胶微球及其制备方法 |
CN107308118A (zh) * | 2017-07-07 | 2017-11-03 | 青岛农业大学 | 一种肺靶向硫酸头孢喹诺plga微球及其制备方法 |
CN107320452A (zh) * | 2017-07-07 | 2017-11-07 | 青岛农业大学 | 一种肺靶向硫酸头孢喹诺ec微球及其制备方法 |
CN107320452B (zh) * | 2017-07-07 | 2020-04-28 | 青岛农业大学 | 一种肺靶向硫酸头孢喹诺ec微球及其制备方法 |
CN107308118B (zh) * | 2017-07-07 | 2020-04-28 | 青岛农业大学 | 一种肺靶向硫酸头孢喹诺plga微球及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN101773478B (zh) | 2012-09-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101756908A (zh) | 聚酯包衣的羟基磷灰石微球及其制备方法 | |
CN101773478B (zh) | 一种兽用头孢噻呋盐酸盐的肺靶向微球及制备方法 | |
US9283190B2 (en) | Highly efficient and long-acting slow-release formulation of poorly soluble drugs and preparation method thereof | |
CN109328249A (zh) | 含有具有可释放掺杂剂的陶瓷颗粒的纳米纤维垫 | |
CN101756910B (zh) | 一种肺靶向头孢噻呋微球及制备方法 | |
US8962017B2 (en) | Formulation of silymarin with high efficacy and prolonged action and the preparation method thereof | |
CN101669917B (zh) | 一种基于“NiMS”系统的氢溴酸东莨菪碱口腔速崩微囊片 | |
US20120029064A1 (en) | formulation of silibinin with high efficacy and prolonged action and the preparation method thereof | |
CN102579365B (zh) | 利培酮微球制剂及其制备方法 | |
CN100428957C (zh) | 一种纤维状磁性药物及其制备方法 | |
CN101756909B (zh) | 肺靶向头孢噻呋微球及制备方法 | |
CN102293748B (zh) | 一种口服聚乙二醇化胰岛素pH敏感纳米粒及其制备方法 | |
CN101804060B (zh) | 一种头孢曲松钠/他唑巴坦钠药物组合物微球注射剂 | |
CN105535970A (zh) | 一种光控茶皂苷元纳米制剂及其制备方法与用途 | |
CN106137955A (zh) | 一种外用噻托溴铵制剂的止汗用途 | |
CN103222962A (zh) | 一种注射用埃索美拉唑组合物及其制备方法 | |
CN101829063B (zh) | 兽用头孢噻呋盐酸盐的肺靶向微球及制备方法 | |
CN101983629B (zh) | 一种哌拉西林钠舒巴坦钠药物组合物微球注射剂 | |
CN101890007A (zh) | 一种阿莫西林钠克拉维酸钾药物组合物微球注射剂 | |
CN102657615A (zh) | 一种长春胺缓释微丸制剂及其制备方法 | |
CN101791410B (zh) | 抗感染药物-多糖偶联物及其药物组合物的制备和应用 | |
CN108143720A (zh) | 可生物降解型止血抗感染的缓释药物组合物及其制备方法 | |
CN105232464A (zh) | 一种盐酸环丙沙星脂质体制剂及其制备方法 | |
CN101773477A (zh) | 一种畜禽用头孢噻呋的肺靶向微球及制备方法 | |
CN109010282A (zh) | 一种头孢克洛缓释制剂的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: QINGDAO KDN PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: QINGDAO CONTINENT BIOTECH CO., LTD. Effective date: 20120405 Owner name: QINGDAO KDN ANIMAL PHARMACEUTICAL CO., LTD. QINGDA Free format text: FORMER OWNER: QINGDAO LIUHE MEDICINE CO., LTD. Effective date: 20120405 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20120405 Address after: 266061 Shandong city of Qingdao province high tech park of Laoshan district by the No. 29 Shandong Road, building 605 high speed Applicant after: QINGDAO KDN PHARMACEUTICAL Co.,Ltd. Co-applicant after: QINGDAO KDN BIOTECH Co.,Ltd. Co-applicant after: Qingdao Agricultural University Address before: 266061 Shandong city of Qingdao province high tech park of Laoshan district by the No. 29 Shandong Road, building 605 high speed Applicant before: Qingdao Vland Biotech INC. Co-applicant before: Qingdao Liuhe Pharmaceuticals Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: QINGDAO WEILAN BIOLOGY CO., LTD. Free format text: FORMER NAME: QINGDAO KDN PHARMACEUTICAL CO., LTD. |
|
CP03 | Change of name, title or address |
Address after: 266061 Shandong city of Qingdao province Chengyang Qingda Industrial Park, the first northbound dual Patentee after: QINGDAO VLAND BIOTECH Inc. Patentee after: QINGDAO KDN BIOTECH Co.,Ltd. Patentee after: Qingdao Agricultural University Address before: 266061 Shandong city of Qingdao province high tech park of Laoshan district by the No. 29 Shandong Road, building 605 high speed Patentee before: QINGDAO KDN PHARMACEUTICAL Co.,Ltd. Patentee before: QINGDAO KDN BIOTECH Co.,Ltd. Patentee before: Qingdao Agricultural University |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120905 |